Article: Scrip Asks...What Does 2024 Hold for Biopharma?
Summary: Scrip recently invited Catalent to share a response for their predictions feature, “What Does 2024 Hold for Biopharma?”. The third of the series, focusing on manufacturing and supply. Catalent’s George Buchman, Ph.D., Research Fellow, Catalent Cell and Gene Therapy, was asked to respond and give insight into trends across cell and gene therapy and what we can expect to witness this year.
KEY LEARNINGS:
- Broad access to cell & gene therapies hinges on continued advances in enabling technologies that improve capabilities, expand applicability and lower manufacturing costs.
- In 2024 and beyond, the field is focused on improving vector capsids, for improved tissue targeting and to modulate immunogenicity, enabling potential re-dosing using the same vector serotype.
- At the same time, we expect to see continued benefit from platform approaches for viral vector process development, production and analytics, driving rapid delivery to first-in-human studies, and streamlining the path to commercial.